Stop Corporate Inversions Act of 2026

The Stop Corporate Inversions Act of 2026 amends Section 7874 of the Internal Revenue Code of 1986, specifically targeting corporate inversions. The bill lowers the ownership threshold for a foreign corporation to be treated as domestic for tax purposes from 80 percent to 60 percent, and introduces a new definition of an "inverted domestic corporation" where management and control are primarily within the United States after an acquisition. This means that many companies that previously inverted to reduce their U.S. tax obligations will now be reclassified as domestic for tax purposes, subjecting their global income to U.S. corporate tax rates. This directly impacts their profitability and cash flow. There is no direct funding mechanism or appropriation in this bill. Instead, it reclaims tax revenue for the U.S. Treasury by closing a tax loophole. Companies that previously engaged in inversions will see their effective tax rates increase, leading to a reduction in their net income. The money trail leads directly to increased tax payments from these corporations to the U.S. government, rather than to specific companies receiving contracts or grants. The primary beneficiaries are U.S. taxpayers through increased government revenue. Historically, efforts to curb corporate inversions have seen mixed results. In 2014, the Treasury Department issued new rules to make inversions more difficult, which led to several planned inversions being called off, including the proposed $160 billion merger between Pfizer ($PFE) and Allergan. Following these actions, companies like Pfizer saw their stock decline as the tax benefits of the inversion were removed. For example, in November 2015, after new Treasury rules were announced, the market reacted negatively to companies perceived as inversion targets. When the Treasury issued new rules in April 2016, Pfizer's stock dropped over 2% in a single day, and Allergan's stock fell over 14% as their inversion deal collapsed. This bill codifies and strengthens similar anti-inversion measures, indicating a direct negative impact on companies that have previously inverted. Specific companies that stand to lose include those that have completed inversions in recent years. Examples include Medtronic ($MDT), which inverted to Ireland in 2015; Stryker ($SYK), which has operations structured to minimize U.S. tax liability; CRH plc ($CRH), an Irish company with significant U.S. operations that benefits from its non-U.S. domicile; Estee Lauder ($EL), which has utilized international tax structures; Perrigo ($PRGO), which inverted to Ireland; TransDigm Group ($TDG), which has a complex international tax structure; Allegion ($ALLE), an Irish-domiciled security company; and Cboe Global Markets ($CBOE), which has international subsidiaries. These companies will face higher U.S. tax liabilities, directly impacting their earnings per share. The bill is currently in the Senate Finance Committee. If it passes the Senate, it moves to the House, and then to the President for signature. Given the bipartisan support for closing tax loopholes, passage is probable, with implementation likely in 2026. This bill has high legislative momentum, with Senator Durbin, a senior Democrat, as the lead sponsor and nine cosponsors, including several influential senators like Elizabeth Warren and Bernie Sanders. The bill's referral to the Committee on Finance, a key committee for tax legislation, further indicates its seriousness. The impact score of 7 reflects the direct and significant financial implications for a defined group of large, publicly traded companies across multiple sectors, and the historical precedent of market reaction to similar anti-inversion measures.